Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2022-07-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Responses will be collected via an FDA application designed to work with a wide range of HMDs and able to display both 2D simple scenes and 3D complete scenes. This application allows a human observer to look at a signal (sinusoidal, disk, sphere, etc.) on a synthetic noisy background or a realistic 3D scene both in virtual reality and augmented reality immersive environments. The application will also provide instructions and a response interface for the observer to respond to questions related to the visibility and to gather task performance measurements.
Participants will not be asked to complete tasks that require specific training or skills. Any adult human with normal or corrected-to-normal vision that can wear an HMD is eligible to participate in this experiment.
Data collected will not include identifiable information. FDA will perform participant enrollment and data collection, ensuring management of PII in accordance with federal rule. Participants will be recruited at will and in person, using promotional materials only containing language within this document. Participants will sign the attached consent form either electronically or by hard copy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility Test of Virtual Reality Obstacle Detection for Low Vision Walking
NCT05141604
Eye Movements in Visual Search
NCT05472961
Development and Validation of a Novel Eye-Tracking Software-based Platform to Extract Oculometric Measures
NCT05476523
Visual Perception Exploration Using Eye-tracking Technology in High-fidelity Medical Simulation
NCT03049098
Moderators and Mediators of Perceptual Learning
NCT05894967
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Positive stimuli
Images/trials that contain a target
Visual stimuli
Stimuli will be shown to participants and they will be asked to perform a visual task.
Negative stimuli
Images/trials that do not contain a target
Visual stimuli
Stimuli will be shown to participants and they will be asked to perform a visual task.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Visual stimuli
Stimuli will be shown to participants and they will be asked to perform a visual task.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No gender requirement
* No sensory, proprioceptive, or neural impairments
* Ability to sit for 20-30 minutes at a time, for up to 2 hours with 5-10 minute breaks
* Adults with normal or corrected-to-normal vision that can wear an HMD comfortably.
* For participants with corrected-to-normal vision and, in the case of an HMD that is not compatible with glasses, contact lenses will be required
Exclusion Criteria
* Uncorrected visual impairments
* Pregnant women
* Participants that have corrected-to-normal vision with glasses that cannot wear the HMD comfortably
* Presence of sensory, proprioceptive, neural, vestibular, or physical impairments that limit fine motor control, gross movement, normal ambulation, or ability to sit/stand as needed for the study
* Claustrophobia such that use of an HMD induces anxiety or other negative psychological response
* Cognitive impairments that limit the ability to comprehend simple written and verbal instructions or identify and locate objects in space
* Subjects with migraine headaches or that experience motion sickness
* Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines (especially with visual aura), or other neurological diseases
* Current medical condition predisposing to nausea, dizziness, or vertigo (e.g. Meniere's disease)
* Ongoing psychosis, hallucinations, or dissociative disorders affecting perception of reality
* Hypersensitivity to flashing light or motion
* Irritated skin or open wounds on the scalp and face where the AR/VR headset will rest
* Past history of use of hallucinogenic medications (e.g. LSD, mesclun, etc.)
* Prior cervical spine disorder or Brachial plexus disorder or shoulder joint disorder, or hand disorder or past surgery in any of the previous stated anatomic areas (as these might affect the use, responsiveness, and/or dexterity of upper extremities or hand-eye coordination)
* Subjects will be excluded from participation in this study if they answer yes to a screening question about taking various medications listed below: (n.b. the reasons for subject being excluded is also noted with the potential side-effects of the noted medication)
* Antihistamines (e.g. diphenhydramine {Benadryl}, etc.) -- Drowsiness, dizziness, constipation, stomach upset, blurred vision, or dry mouth/nose/throat may occur.
* Muscle relaxants (e.g. methocarbamol {Robaxin}, cyclobenzaprine {Flexeril}, carisoprodol {Soma} , etc.) -- Drowsiness, tiredness, clumsiness, headache, dizziness, lightheadedness, dry mouth, stomach upset, nausea/vomiting, or blurred vision may occur.
* Analgesic medications (e.g. narcotics, Class II controlled substances such as propoxyphene {Darvon} , etc.) -- Low blood pressure, drowsiness, fainting, dizziness, nausea, vomiting, generalized weakness, a feeling of general discomfort called malaise.
* Sleep medications (e.g. zolpridem {Ambien}, etc.) -- Daytime drowsiness, dizziness, weakness, feeling "drugged" or light-headed; tired feeling, loss of coordination; memory loss, stuffy nose, dry mouth, nose or throat irritation; nausea, constipation, diarrhea, upset stomach, headache, muscle pain, anxiety, depression, aggression, agitation, confusion, or hallucinations (hearing or seeing.) This is not a complete list of side effects and others may occur.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Food and Drug Administration (FDA)
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
10903 New Hampshire Ave, WO62
Silver Spring, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USFDA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.